GRIP Molecular Technologies, Inc
Doug Franz is a seasoned professional with extensive experience in technology commercialization and medical device consulting. Currently serving as a Technology Licensing Officer at the University of Minnesota since August 2019, Doug collaborates with faculty, physicians, and researchers to advance medical device innovations. As a Board Member at GRIP Molecular Technologies, Inc. and former Founder of Interyl Consulting, Doug has guided businesses in product development and supply chain challenges. Formerly, Doug held significant leadership roles at Altek Corporation as Corporate Vice President and General Manager of the Medical Business Unit, and across various positions at HP, where Doug drove research and development efforts for digital cameras and office printers. Doug holds a Master of Science in Electrical and Electronics Engineering from Stanford University and a Bachelor of Science in Electrical and Electronics Engineering from Iowa State University.
This person is not in the org chart
This person is not in any teams
GRIP Molecular Technologies, Inc
GRIP Molecular is developing a novel, patent-protected, chip-based electronic biosensor that will provide lab-grade diagnostic results in minutes using a mobile device at the point of need. Unlike existing diagnostic technologies, it has the capability to simultaneously detect various diseases and characterize their state of infection (infectious to immune) with a single test. GRIP uses a combination of novel nanomaterials and patented 3D printing to deliver accurate results in minutes without the burden of complex chemistry. The appearance of COVID-19 as a global health threat has increased the urgency to transform diagnostics, which the GRIP team was well into even before this threat emerged. The ability to quickly, easily and cost-effectively test for active infection and immunity at the point of need has become the new baseline for what we should expect for early detection of all kinds of disease, but particularly when fighting a pandemic level enemy. GRIP is committed to confirm the science and commercialize a new approach with a number of specific panels/products that address our most challenging diseases and chronic conditions.